MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woodward, R. M.
Right arrow Articles by Weber, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodward, R. M.
Right arrow Articles by Weber, E.

In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D- aspartate receptor glycine sites

RM Woodward, JE Huettner, J Guastella, JF Keana and E Weber

Acea Pharmaceuticals Inc., Irvine, California 92715.

N-methyl-D-aspartate (NMDA) receptor antagonists show therapeutic potential as neuroprotectants, analgesics, and anticonvulsants. In this context, we used electrical recording techniques to study the in vitro pharmacology of two novel quinoxalinediones, i.e., ACEA-1021 and ACEA- 1031 (5-nitro-6,7- dichloro- and 5-nitro-6,7-dibromo-1,4-dihydro-2,3- quinoxalinedione, respectively). Assays with NMDA receptors expressed by rat brain poly(A)+ RNA in Xenopus oocytes and with NMDA receptors in cultured rat cortical neurons indicated that ACEA-1021 and ACEA-1031 are potent competitive antagonists at NMDA receptor glycine sites. Apparent dissociation constants (Kb values) for ACEA-1021 and ACEA-1031 ranged between 6 and 8 nM for oocyte assays and between 5 and 7 nM for neuronal assays. Cloned NMDA receptors expressed in oocytes showed up to 50-fold variation in sensitivity, depending upon subunit composition. For example, using fixed agonist concentrations (10 microM glycine and 100 microM glutamate) IC50 values for ACEA-1021 with four binary combinations were as follows: NMDA receptor (NR)1A/2A, 29 nM; NR1A/2B, 300 nM; NR1A/2C, 120 nM; NR1A/2D, 1500 nM. Measurement of EC50 for glycine and calculation of Kb for the inhibitors indicated that differences in IC50 values are due to subunit-dependent variations in glycine affinity (EC50 ranged between approximately 0.1 and 1 microM) combined with variations in affinity of the antagonists themselves (Kb of approximately 2-13 nM). In addition to the strong antagonism of NMDA receptors, ACEA-1021 and ACEA-1031 were also moderately potent competitive inhibitors of non-NMDA receptors activated either by alpha- amino-3-hydroxy-5-methylisoxazole-4-propionic acid or by kainate. Antagonist affinities were similar whether measured with receptors expressed by rat brain poly(A)+ RNA in oocytes (Kb of 1-2 microM) or with cultured neurons (Kb of 1.5-3.3 microM). Our results suggest that the in vivo neuro-protective actions of ACEA-1021 and ACEA-1031 are predominantly due to inhibition at NMDA receptor glycine sites, although additional inhibition at non-NMDA receptors may play an ancillary role.

Volume 47, Issue 3, pp. 568-581, 03/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J Child NeurolHome page
T. A. Simeone, R. M. Sanchez, and J. M. Rho
Molecular Biology and Ontogeny of Glutamate Receptors in the Mammalian Central Nervous System
J Child Neurol, May 1, 2004; 19(5): 343 - 360.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. J. Blanchet, S. Konitsiotis, E. R. Whittemore, Z. L. Zhou, R. M. Woodward, and T. N. Chase
Differing Effects of N-methyl-D-aspartate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-phenyl-tetrahydropyridine Monkeys
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1034 - 1040.
[Abstract] [Full Text]


Home page
StrokeHome page
G. W. Albers, W. M. Clark, R. P. Atkinson, K. Madden, J. L. Data, and M. J. Whitehouse
Dose Escalation Study of the NMDA Glycine-Site Antagonist Licostinel in Acute Ischemic Stroke
Stroke, March 1, 1999; 30(3): 508 - 513.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
W. Danysz and C. G. Parsons
Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications
Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. E. Hawkinson, M. Acosta-Burruel, K. C. Yang, D. J. Hogenkamp, J.-S. Chen, N. C. Lan, J. A. Drewe, E. R. Whittemore, R. M. Woodward, R. B. Carter, et al.
Substituted 3beta -Phenylethynyl Derivatives of 3alpha -Hydroxy-5alpha -pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of gamma -Aminobutyric AcidA Receptors
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 198 - 207.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
I. O. Medvedev, O. A. Dravolina, and A. Y. Bespalov
Effects of N-Methyl-D-Aspartate Receptor Antagonists on Discriminative Stimulus Effects of Naloxone in Morphine-Dependent Rats Using the Y-Maze Drug Discrimination Paradigm
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1260 - 1268.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward
Antagonism of N-Methyl-D-Aspartate Receptors by sigma  Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition
J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
T. J. Wilding and J. E. Huettner
Activation and Desensitization of Hippocampal Kainate Receptors
J. Neurosci., April 15, 1997; 17(8): 2713 - 2721.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics